Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Arena Pharmaceuticals

Related ARNA
What's Driving Orexigen Therapeutics Higher?
Arena Pharmaceuticals Reports Q3 Loss, Shares Surge 6%

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Arena Pharmaceuticals (NASDAQ: ARNA), but lowered its price target from $20.00 to $14.00.

Jefferies noted, “ARNA reiterated its plans for Belviq (1Q13 U.S. launch) and outlined a new South Korean partnership with Ildong. We remain confident in the long-term potential for Belviq based on combination use with phentermine, but we are lowering our PT from $20 to $14, as we moderate our launch expectations for Belviq monotherapy following disappointing sales for competitor Qsymia.”

Arena Pharmaceuticals closed on Tuesday at $7.60.

Latest Ratings for ARNA

DateFirmActionFromTo
Nov 2013WallachbethInitiates Coverage onBuy
Oct 2013Cowen & CompanyInitiates Coverage onMarket Perform
Oct 2013Piper JaffrayMaintainsOverweight

View More Analyst Ratings for ARNA
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (ARNA)

Around the Web, We're Loving...

Get Benzinga's Newsletters